Table 1.
Characteristics and Clinical Outcomes of patient.
| Patient characteristic | Total | Number | % |
|---|---|---|---|
| Total patient | 1004 | ||
| Median age(range) | 1004 | 58(26–82) | |
| Age | 1004 | ||
| ≤58 | 518 | 51.6 | |
| >58 | 486 | 48.4 | |
| Gender | 1004 | ||
| Male | 706 | 70.3 | |
| Female | 298 | 29.7 | |
| TNM Stage | 999 | ||
| IIIA | 81 | 8.1 | |
| IIIB | 293 | 29.3 | |
| IV | 625 | 62.6 | |
| ECOG PS | 990 | ||
| 0–1 | 904 | 91.3 | |
| 2 | 86 | 8.7 | |
| Histological Type | 1004 | ||
| Adenocarcinoma | 632 | 62.9 | |
| Squamous Cell Carcinoma | 221 | 22.0 | |
| Adenosquamocarcinoma | 20 | 2.0 | |
| Othersa | 131 | 13.1 | |
| Smoking Statusb | 1000 | ||
| Never smoker | 425 | 42.5 | |
| Ever smoker | 575 | 57.5 | |
| Chemotherapy Regimens | 1004 | ||
| Platinum-navelbine | 316 | 31.5 | |
| Platinum-gemcitabine | 239 | 23.8 | |
| Platinum-paclitaxel | 313 | 31.1 | |
| Platinum-docetaxel | 87 | 8.7 | |
| Others platinum combinations | 49 | 4.9 | |
| Objective Response | 975 | ||
| CR | 1 | 0.1 | |
| PR | 176 | 18.1 | |
| SD | 610 | 60.0 | |
| PD | 188 | 19.3 | |
| Severe gastrointestinal toxicity | 964 | 80 | 8.3 |
| Severe hematological toxicity | 969 | ||
| Anemia | 944 | 29 | 3.1 |
| Neutropenia | 935 | 115 | 12.3 |
| Thrombocytopenia | 950 | 34 | 3.6 |
| Median Time to outcomes (month) | 972 | ||
| PFS | 896 | 9.1 | |
| OS | 972 | 19.3 |
ECOG PS, Eastern Cooperative Oncology Group performance status; TNM, tumor-node metastasis; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; PFS, progression-free survival (months); OS, overall survival (months).
aOther carcinomas included mixed cell or undifferentiated carcinoma.
bNonsmokers were defined as those who had smoked <1 cigarette per day and for <1 year in their lifetime.